Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GS-1811 |
| Synonyms | |
| Therapy Description |
GS-1811 is a monoclonal antibody targeted against CCR8, which potentially induces antibody-dependent cell mediated cytotoxicity (ADCC) and depletion of tumor-infiltrating regulatory T cells (Tregs) (Cancer Res 2020;80(16 Suppl):Abstract nr 4532). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GS-1811 | GS1811|GS 1811|JTX 1811|JTX1811|JTX-1811 | CCR8 Antibody 13 | GS-1811 is a monoclonal antibody targeted against CCR8, which potentially induces antibody-dependent cell mediated cytotoxicity (ADCC) and depletion of tumor-infiltrating regulatory T cells (Tregs) (Cancer Res 2020;80(16 Suppl):Abstract nr 4532). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05007782 | Phase I | GS-1811 GS-1811 + Pembrolizumab | Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | Recruiting | USA | ESP | CAN | AUS | 1 |